Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
SLB, Travelers Companies And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today…
(GIS) – Analyzing General Mills’s Short Interest
General Mills’s (NYSE:GIS) short percent of float has fallen 6.91% since its last report. The company recently reported that it…
Footwear Company Caleres Issues 2026 Financial Targets Ahead Of Investor Day Event
Caleres Inc (NYSE:CAL) put forward its three-year strategic and financial plan in conjunction with its Oct. 5 Investor Day. The…